Recent Updates
Recently added Catalysts
URGN Positive Sentiment

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Wednesday, August 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: UroGen reported a revenue of $50.4 million for ZUSDURI in Q2 2026, marking a significant 73% growth compared to the previous quarter. The company anticipates a new U.S. patent that will protect ZUSDURI and UGN-103 until July 2044. Additionally, UGN-103 is progressing towards its NDA submission.

Market Sentiment Analysis

POSITIVE FACTORS

  • ZUSDURI generated $50.4 million in revenue.
  • 73% quarter-over-quarter growth in revenue.
  • New U.S. patent expected to provide protection until July 2044.
  • Advancement of pipeline with UGN-103 on track for NDA submission.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Lead asset
UGN-101 instillations
Phase 3 · Carcinoma, Transitional Cell

Full Press Release Details

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103 Continued advancement of pipeline, with UGN-103 on track for NDA submission

Frequently Asked Questions

What revenue did UroGen report for ZUSDURI in Q2 2026?

UroGen reported $50.4 million in revenue for ZUSDURI in Q2 2026.

What was the growth percentage for ZUSDURI revenue?

ZUSDURI revenue grew by 73% quarter-over-quarter.

When is the new U.S. patent for ZUSDURI expected?

The new U.S. patent is expected to provide protection until July 2044.

What is the status of UGN-103?

UGN-103 is on track for NDA submission.

ShareAdd on Google
Tags: URGN Viatris Investor Conferences Healthcare UroGen ZUSDURI UGN-103 NDA submission financial results
Last updated: Aug 5, 2026

Biotech snapshot

Cash runway
$109M liquidity · $0M/mo burn
Low dilution risk
Lead asset
UGN-101 instillationsPhase 3
Carcinoma, Transitional Cell →

Catalyst track record

+124%
best trade around URGN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for URGN.

See every catalyst's timing & PoA →